Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 7/20 | 0.46 |
| ▸ | SRC | P12931 | 4/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.42 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 5/20 | 0.41 |
| ▸ | ABL1 | P00519 | 4/20 | 0.41 |
| ▸ | ABL2 | P42684 | 4/20 | 0.41 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.40 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16655432 | 0.93 | SRC (0.44) | ATRSRCPIK3CDBTKEGFR | |
| SCHEMBL16655829 | 0.85 | PIK3CD (0.48) | ATRSRCPIK3CDBTKEGFR | |
| SCHEMBL16655547 | 0.85 | PIK3CD (0.48) | ATRSRCPIK3CDBTKEGFR | |
| SCHEMBL16655728 | 0.82 | PIK3CD (0.51) | ATRSRCPIK3CDBTKRIPK2 | |
| SCHEMBL16655550 | 0.80 | ATR (0.56) | ATRPIK3CDBTKPIK3CAPIK3CB | |
| SCHEMBL16665718 | 0.79 | SRC (0.38) | SRCBTKEGFRABL1ABL2 | |
| SCHEMBL16654211 | 0.78 | ATR (0.54) | ATRSRCPIK3CDBTKEGFR | |
| SCHEMBL16655663 | 0.77 | PIK3CD (0.49) | ATRSRCPIK3CDBTKEGFR | |
| SCHEMBL16655472 | 0.77 | PIK3CD (0.49) | ATRSRCPIK3CDBTKEGFR | |
| SCHEMBL16655242 | 0.74 | ATR (0.48) | ATRPIK3CDBTKPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | claimed |
| EP-3057970-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2016-08-24 | — | — | EP | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | claimed |
| WO-2015058084-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | ATR 680/4885SRC 92/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.